• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有二元终点的贝叶斯多臂多阶段临床试验的模拟优化

Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.

作者信息

Yu Zhenning, Ramakrishnan Viswanathan, Meinzer Caitlyn

机构信息

a Graduate Research Assistant, Data Coordination Unit, Department of Public Health Sciences , Medical University of South Carolina , Charleston , SC , USA.

b Department of Public Health Sciences , Medical University of South Carolina , Charleston , SC , USA.

出版信息

J Biopharm Stat. 2019;29(2):306-317. doi: 10.1080/10543406.2019.1577682. Epub 2019 Feb 14.

DOI:10.1080/10543406.2019.1577682
PMID:30763151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7751063/
Abstract

Multi-arm multi-stage designs, in which multiple active treatments are compared to a control and accumulated information from interim data are used to add or remove arms from the trial, may reduce development costs and shorten the drug development timeline. As such, this adaptive update is a natural complement to Bayesian methodology in which the prior clinical belief is sequentially updated using the observed probability of success. Simulation is often required for planning clinical trials to accommodate the complexity of the design and to optimize key design characteristics. This paper addresses two key limiting factors in simulations, namely the computational burden and the time needed to obtain results. We first introduce a generic process for simulating Bayesian multi-arm multi-stage designs with binary endpoints. Then, to address the computational burden and time, we optimize the method for calculating the posterior probability and posterior predictive probability of success.

摘要

多臂多阶段设计是将多种活性治疗与一种对照进行比较,并利用中期数据积累的信息来增加或减少试验中的臂数,这种设计可能会降低研发成本并缩短药物研发时间线。因此,这种适应性更新是贝叶斯方法的自然补充,在贝叶斯方法中,先前的临床信念会根据观察到的成功概率进行顺序更新。规划临床试验时通常需要进行模拟,以适应设计的复杂性并优化关键设计特征。本文探讨了模拟中的两个关键限制因素,即计算负担和获得结果所需的时间。我们首先介绍一种用于模拟具有二元终点的贝叶斯多臂多阶段设计的通用过程。然后,为了解决计算负担和时间问题,我们优化了计算成功的后验概率和后验预测概率的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/ab9159858f48/nihms-1535430-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/fd010115be34/nihms-1535430-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/b955db0cbb28/nihms-1535430-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/ab9159858f48/nihms-1535430-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/fd010115be34/nihms-1535430-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/b955db0cbb28/nihms-1535430-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eac/7751063/ab9159858f48/nihms-1535430-f0003.jpg

相似文献

1
Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.具有二元终点的贝叶斯多臂多阶段临床试验的模拟优化
J Biopharm Stat. 2019;29(2):306-317. doi: 10.1080/10543406.2019.1577682. Epub 2019 Feb 14.
2
Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.使用未知形状参数的 Weibull 分布对具有时间事件终点的单臂临床试验进行样本量重估和贝叶斯预测概率。
J Biopharm Stat. 2024 Jul 3;34(4):469-487. doi: 10.1080/10543406.2023.2234998. Epub 2023 Aug 6.
3
Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.贝叶斯自适应决策理论设计在多臂多阶段临床试验中的应用。
Stat Methods Med Res. 2021 Mar;30(3):717-730. doi: 10.1177/0962280220973697. Epub 2020 Nov 26.
4
Group sequential multi-arm multi-stage survival trial design with treatment selection.具有治疗选择的分组序贯多臂多阶段生存试验设计。
J Biopharm Stat. 2024 Jul 3;34(4):453-468. doi: 10.1080/10543406.2023.2235409. Epub 2023 Jul 16.
5
Bayesian optimal phase II clinical trial design with time-to-event endpoint.贝叶斯最优设计的Ⅱ期临床试验设计,以时间为终点事件。
Pharm Stat. 2020 Nov;19(6):776-786. doi: 10.1002/pst.2030. Epub 2020 Jun 10.
6
A hybrid Bayesian adaptive design for dose response trials.一种用于剂量反应试验的混合贝叶斯自适应设计。
J Biopharm Stat. 2005;15(4):677-91. doi: 10.1081/BIP-200062288.
7
A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.一种用于单臂探索性临床试验的贝叶斯预测性样本量选择设计。
Stat Med. 2012 Dec 30;31(30):4243-54. doi: 10.1002/sim.5505. Epub 2012 Jul 16.
8
A simulation study of outcome adaptive randomization in multi-arm clinical trials.多臂临床试验中结局自适应随机化的模拟研究。
Clin Trials. 2017 Oct;14(5):432-440. doi: 10.1177/1740774517692302. Epub 2017 Feb 1.
9
Predictive probability of success using surrogate endpoints.使用替代终点预测成功率。
Stat Med. 2019 May 10;38(10):1753-1774. doi: 10.1002/sim.8060. Epub 2018 Dec 12.
10
Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.临床试验中二元结局数据的期中分析:五种估计量的比较
J Biopharm Stat. 2019;29(2):400-410. doi: 10.1080/10543406.2018.1559852. Epub 2019 Jan 1.

引用本文的文献

1
Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.多臂临床试验中的适应性治疗分配和选择:贝叶斯视角。
BMC Med Res Methodol. 2022 Feb 20;22(1):50. doi: 10.1186/s12874-022-01526-8.
2
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19.针对COVID-19干预措施临床试验的高效自适应设计
Stat Biopharm Res. 2020 Jul 29;12(4):483-497. doi: 10.1080/19466315.2020.1790415.

本文引用的文献

1
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.用于II期药物筛选试验的多臂多阶段贝叶斯设计评估——血液肿瘤学中的一个例子
BMC Med Res Methodol. 2016 Jun 2;16:67. doi: 10.1186/s12874-016-0166-7.
2
Controlled multi-arm platform design using predictive probability.采用预测概率的对照多臂平台设计
Stat Methods Med Res. 2018 Jan;27(1):65-78. doi: 10.1177/0962280215620696. Epub 2016 Jan 12.
3
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
二十五年的验证性适应性设计:机遇与陷阱。
Stat Med. 2016 Feb 10;35(3):325-47. doi: 10.1002/sim.6472. Epub 2015 Mar 16.
4
Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.用于将多种实验性治疗与对照进行比较的探索性临床试验的贝叶斯样本量。
Stat Med. 2015 May 30;34(12):2048-61. doi: 10.1002/sim.6469. Epub 2015 Mar 12.
5
More multiarm randomised trials of superiority are needed.需要更多的多臂优效性随机试验。
Lancet. 2014 Jul 26;384(9940):283-4. doi: 10.1016/S0140-6736(14)61122-3.
6
The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.贝叶斯预测概率在临床试验中期监测中的效用。
Clin Trials. 2014 Aug;11(4):485-493. doi: 10.1177/1740774514531352. Epub 2014 May 28.
7
Bayesian hypothesis testing in two-arm trials with dichotomous outcomes.双臂二分结果试验中的贝叶斯假设检验。
Biometrics. 2013 Mar;69(1):157-63. doi: 10.1111/j.1541-0420.2012.01806.x. Epub 2012 Sep 24.
8
Optimal design of multi-arm multi-stage trials.多臂多阶段试验的优化设计。
Stat Med. 2012 Dec 30;31(30):4269-79. doi: 10.1002/sim.5513. Epub 2012 Jul 23.
9
A Bayesian inference of P(π1 > π2) for two proportions.两个比例的P(π1 > π2)的贝叶斯推断。
J Biopharm Stat. 2012;22(3):425-37. doi: 10.1080/10543406.2010.544438.
10
Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.基于缺乏获益的停止标准的时间事件结局临床试验设计。
Trials. 2011 Mar 18;12:81. doi: 10.1186/1745-6215-12-81.